Zentalis Pharmaceuticals, Inc.
ZNTL
$2.76
$0.093.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -33.76% | -33.76% | -33.76% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -33.76% | -33.76% | -33.76% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -33.76% | -33.76% | -33.76% | -- |
| SG&A Expenses | -62.77% | 8.18% | 11.83% | 28.61% | 35.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.71% | -28.17% | -24.50% | -10.59% | 0.37% |
| Operating Income | 24.82% | 27.09% | 22.79% | 6.19% | 26.18% |
| Income Before Tax | 17.55% | 16.51% | 16.15% | -2.09% | 43.43% |
| Income Tax Expenses | 149.72% | -183.00% | -176.07% | 106.01% | 129.45% |
| Earnings from Continuing Operations | 17.37% | 16.74% | 16.40% | -2.37% | 43.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -100.00% | -100.00% | -100.00% | -75.44% |
| Net Income | 17.35% | 16.72% | 16.37% | -2.41% | 43.24% |
| EBIT | 24.82% | 27.09% | 22.79% | 6.19% | 26.18% |
| EBITDA | 24.70% | 27.06% | 22.81% | 6.17% | 26.28% |
| EPS Basic | 18.15% | 17.51% | 17.08% | 6.21% | 48.92% |
| Normalized Basic EPS | 14.68% | 14.06% | 13.84% | -0.82% | 47.81% |
| EPS Diluted | 18.22% | 17.58% | 17.14% | 6.27% | 48.91% |
| Normalized Diluted EPS | 14.70% | 14.08% | 13.86% | -0.80% | 47.79% |
| Average Basic Shares Outstanding | 1.11% | 1.13% | 0.94% | 4.38% | 8.72% |
| Average Diluted Shares Outstanding | 1.00% | 1.02% | 0.84% | 4.27% | 8.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |